Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
MiNK Therapeutics reports complete remission in advanced testicular cancer patient using their new cell therapy.
MiNK Therapeutics announced a groundbreaking case of a patient with advanced, treatment-resistant testicular cancer achieving complete remission after receiving their experimental off-the-shelf iNKT cell therapy, agenT-797, alongside nivolumab.
The treatment, which was well-tolerated, has led to a significant increase in the company's stock price.
AgenT-797 is currently in clinical trials for various cancers, including gastric cancer, and the success of this case could expand its use in treating other solid tumors.
7 Articles
MiNK Therapeutics informa una remisión completa en pacientes con cáncer testicular avanzado usando su nueva terapia celular.